Blocking ROR1 enhances the roles of erlotinib in lung adenocarcinoma cell lines
Wang, Hui-Li1; Liu, Yan-Chun2; Long, Ming-Peng1; Zheng, Chuan1; Yang, Jia-Hui1
Corresponding AuthorZheng, Chuan( ; Yang, Jia-Hui(
Source PublicationONCOLOGY LETTERS
AbstractTreatment strategies involving tyrosine kinase inhibitors (TKIs) for patients with non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) mutations have advanced significantly; however, challenges still remain regarding the development of resistance. It has been reported that receptor tyrosine kinase-like orphan receptor 1 (ROR1) acts as a hepatocyte growth factor receptor (MET) and c-Src substrate, and that the extracellular domain of ROR1 is associated with EGFR to sustain EGFR-ERBB3-PI3K signaling. Our previous study reported that blocking ROR1 significantly decreased the activity of key signal molecules in the AKT/mammalian target of rapamycin (mTOR) signaling pathway, which was associated with a significant increase of apoptosis and significant decrease of proliferation of lung adenocarcinoma cells. The present study hypothesized that inhibiting ROR1 could potentially prevent erlotinib resistance in NSCLC cell lines. Investigations were performed with two erlotinib-resistant cell lines XLA-07 and NCI-H1975, and an erlotinib-acquired-resistant cell line PC-9erlo, which was developed from its parental cell line PC-9. It was identified that the inhibition of ROR1 via small interfering RNA treatment significantly improved the anti-proliferation and apoptosis-inducing roles of erlotinib in TKI-resistant tumor cells. This was in accordance with the activity of key molecules of the AKT/mTOR signaling pathway, including glycogen synthase kinase-3 alpha/beta (GSK-3 alpha/beta), phosphatase and tensin homolog (PTEN), AKT, mTOR and ribosomal protein S6 kinase beta-1 (p70S6K). The current data suggest that targeting ROR1 is a potential novel treatment strategy for patients with ROR1-positive NSCLC, particularly those with acquired resistance to EGFR-TKI.
Keywordreceptor tyrosine kinase-like orphan receptor 1 lung adenocarcinoma erlotinib resistance AKT mammalian target of rapamycin small interfering RNA
Indexed BySCI
WOS IDWOS:000487675500101
Citation statistics
Document Type期刊论文
Corresponding AuthorZheng, Chuan; Yang, Jia-Hui
Affiliation1.Chengdu Univ Tradit Chinese Med, Sch Basic Med, 1166 Liutai Ave, Chengdu 611137, Sichuan, Peoples R China
2.Chinese Acad Sci, Kunming Inst Bot, State Key Lab Phytochem & Plant Resources West Ch, Kunming 650201, Yunnan, Peoples R China
Recommended Citation
GB/T 7714
Wang, Hui-Li,Liu, Yan-Chun,Long, Ming-Peng,et al. Blocking ROR1 enhances the roles of erlotinib in lung adenocarcinoma cell lines[J]. ONCOLOGY LETTERS,2019,18(3):2977-2984.
APA Wang, Hui-Li,Liu, Yan-Chun,Long, Ming-Peng,Zheng, Chuan,&Yang, Jia-Hui.(2019).Blocking ROR1 enhances the roles of erlotinib in lung adenocarcinoma cell lines.ONCOLOGY LETTERS,18(3),2977-2984.
MLA Wang, Hui-Li,et al."Blocking ROR1 enhances the roles of erlotinib in lung adenocarcinoma cell lines".ONCOLOGY LETTERS 18.3(2019):2977-2984.
Files in This Item: Download All
File Name/Size DocType Version Access License
Wang-2019-Blocking R(667KB)期刊论文出版稿开放获取CC BY-NC-SAView Download
Related Services
Recommend this item
Usage statistics
Export to Endnote
Google Scholar
Similar articles in Google Scholar
[Wang, Hui-Li]'s Articles
[Liu, Yan-Chun]'s Articles
[Long, Ming-Peng]'s Articles
Baidu academic
Similar articles in Baidu academic
[Wang, Hui-Li]'s Articles
[Liu, Yan-Chun]'s Articles
[Long, Ming-Peng]'s Articles
Bing Scholar
Similar articles in Bing Scholar
[Wang, Hui-Li]'s Articles
[Liu, Yan-Chun]'s Articles
[Long, Ming-Peng]'s Articles
Terms of Use
No data!
Social Bookmark/Share
File name: Wang-2019-Blocking ROR1 enhances the roles of.pdf
Format: Adobe PDF
All comments (0)
No comment.

Items in the repository are protected by copyright, with all rights reserved, unless otherwise indicated.